Hepion Dismisses Grassi & Co., Hires RRBB as New Auditor
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals replaced its independent auditor, dismissing Grassi & Co. and hiring RRBB for the fiscal year ending December 31, 2026. No disagreements were reported, but the change follows going concern warnings and material weaknesses in internal controls.
Key Events · Corporate Governance and Compliance · CTRVP
-
Auditor Dismissal and New Engagement
Audit committee approved dismissal of Grassi & Co. and engagement of Rosenberg Rich Baker Berman P.A. (RRBB) on September 21, 2026; Grassi informed September 22, effective immediately.
-
Going Concern and Material Weaknesses
Grassi's prior audit reports contained going concern explanatory paragraphs; material weaknesses in internal control over financial reporting were disclosed in prior 10-K and 10-Q filings and discussed with Grassi.
-
No Disagreements or Reportable Events
No disagreements on accounting principles, financial statement disclosure, or auditing scope/procedure; no reportable events other than the previously disclosed material weaknesses.
-
Exhibit 16.1 Letter from Grassi
Grassi furnished a letter dated September 24, 2026, agreeing with the statements concerning its firm in the 8-K.
Analysis · CTRVP · Life Sciences
Hepion Pharmaceuticals dismissed its auditor Grassi & Co. and engaged Rosenberg Rich Baker Berman P.A. effective September 22, 2026. The change comes amid a going concern warning and previously disclosed material weaknesses in internal controls — a governance red flag for a company already trading near its 52-week high on OTC QB. The filing states there were no disagreements or reportable events with Grassi, but the auditor switch during a period of financial distress warrants close attention.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.